Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Biosimilars: SOP for Carbon Dioxide Sparging – V 2.0

Posted on By


Biosimilars: SOP for Carbon Dioxide Sparging – V 2.0

/>

Standard Operating Procedure for Carbon Dioxide Sparging in Biosimilar Bioreactor Operations

Department Biosimilars
SOP No. SOP/BS/106/2025
Supersedes SOP/BS/106/2022
Page No. Page 1 of 11
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To define the procedure for carbon dioxide (CO₂) sparging in bioreactor systems during biosimilar upstream processes, primarily for pH control and maintaining an optimal environment for cell culture growth.

2. Scope

This SOP applies to all production-scale and pilot-scale bioreactor systems equipped with pH control modules that utilize CO₂ sparging as a corrective mechanism within the biosimilar manufacturing facility.

3. Responsibilities

  • Production Operator: Monitor and execute CO₂ sparging based on pH readings and process setpoints.
  • Supervisor: Approve manual sparging actions and review sparging logs.
  • Engineering: Maintain and calibrate flow meters and CO₂ delivery systems.
See also  Biosimilars: SOP for Water for Injection (WFI) Systems Usage - V 2.0

4. Accountability

The Head of Production is accountable for ensuring the proper control and documentation of carbon dioxide sparging activities to maintain pH within acceptable process limits.

5. Procedure

5.1 System Setup and Pre-Check

  1. Verify CO₂ gas line is connected to the bioreactor gas mixing panel.
  2. Ensure CO₂ supply is medical grade or as per approved specification.
  3. Check leak-free connections and confirm functionality of backpressure regulators.

5.2 Setting pH Control Strategy

  1. Set desired pH control band (e.g., 7.0 ± 0.2) in the SCADA/control system.
  2. Define control cascade: Acid (CO₂) as primary downtrend mechanism, base (e.g., NaOH) as uptrend.

5.3 Initiating CO₂ Sparging

  1. If pH rises above upper setpoint, automated CO₂ sparging is triggered through MFC (Mass Flow Controller).
  2. For manual sparging:
    • Obtain supervisor approval.
    • Initiate flow through CO₂ inlet line at 0.01–0.05 vvm based on vessel volume.
  3. Monitor pH response continuously during enrichment.
See also  Biosimilars: SOP for Viral Inactivation via Low pH Treatment - V 2.0

5.4 Monitoring and Documentation

  1. Log all CO₂ sparging events in Annexure-1 with time, duration, flow rate, and pH change.
  2. Ensure stable pH within control range is achieved within 15–30 minutes of sparging.

5.5 Post-Sparging Actions

  1. Close manual CO₂ flow valves and return control to automatic mode if overridden.
  2. Check for any foaming issues or DO shifts post-sparging.
  3. Notify Engineering if sparging is ineffective or erratic.

6. Abbreviations

  • CO₂: Carbon Dioxide
  • vvm: Volume of gas per volume of liquid per minute
  • MFC: Mass Flow Controller
  • SCADA: Supervisory Control and Data Acquisition

7. Documents

  1. CO₂ Sparging Log – Annexure-1
  2. CO₂ Flow Meter Calibration Record – Annexure-2
See also  Biosimilars: SOP for Microbial Contamination Check During Culture in Bioreactor Operations - V 2.0

8. References

  • ICH Q10 – Pharmaceutical Quality System
  • FDA Guidance on Process Control and Monitoring (2023)

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: CO₂ Sparging Log

Date Batch No. Initial pH Flow Rate (vvm) Start–End Time Final pH Performed By
04/05/2025 BS-215 7.3 0.03 10:10–10:30 7.0 Sunita Reddy

Annexure-2: CO₂ Flow Meter Calibration Record

Equipment ID Last Calibrated Due Date Status Calibrated By
MFC-CO2-204 01/04/2025 01/10/2025 OK Ajay Verma

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Added flow rate limits, alarm response, and calibration annexure GMP process control update
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: Sterile Injectable Manufacturing: SOP for Operation of Laminar Flow Cabinets during Aseptic Processing – V 2.0
Next Post: Elixir Department: SOP for Transfer of Final Bulk for Bottling – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version